-
Mashup Score: 2Belzutifan Displays Robust Activity in VHL-Associated RCC - 2 day(s) ago
Belzutifan was safe and effective in patients with von Hippel-Lindau–associated RCC and other neoplasms.
Source: www.onclive.comCategories: General Medicine NewsTweet
-
Mashup Score: 4Belzutifan Displays Robust Activity in VHL-Associated RCC - 5 day(s) ago
Belzutifan was safe and effective in patients with von Hippel-Lindau–associated RCC and other neoplasms.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Treatment with belzutifan led to high response rates in patients with VHL-associated #RCC and other neoplasms, according to data from the phase 2 LITESPARK-004 trial. #KidneyCancer #kcsm Read more here: https://t.co/9JbbfsuPkv https://t.co/wvTAaTAvMZ
-
At a median follow-up of 49.9 months, patients with #RCC who received the small-molecule HIF-2α inhibitor achieved an ORR of 67%. #KidneyCancer #kcsm Read more data here: https://t.co/bpgMEp6dq3